Investors sold shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on strength during trading on Thursday. $287.60 million flowed into the stock on the tick-up and $317.08 million flowed out of the stock on the tick-down, for a money net flow of $29.48 million out of the stock. Of all equities tracked, Valeant Pharmaceuticals International had the 0th highest net out-flow for the day. Valeant Pharmaceuticals International traded up $1.40 for the day and closed at $23.02

Several brokerages recently issued reports on VRX. Rodman & Renshaw reiterated a “buy” rating and set a $105.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, April 26th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, April 26th. Canaccord Genuity reiterated a “hold” rating and set a $40.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday, April 27th. Guggenheim reiterated a “buy” rating and set a $55.00 price target on shares of Valeant Pharmaceuticals International in a research report on Monday, April 25th. Finally, Wells Fargo & Co. reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, April 25th. Seven equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $66.43.

The firm has a 50 day moving average price of $23.63 and a 200-day moving average price of $50.23. The stock’s market capitalization is $7.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, missing analysts’ consensus estimates of $1.37 by $0.10. The business earned $2.37 billion during the quarter, compared to analyst estimates of $2.34 billion. The firm’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.36 EPS. On average, analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.63 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa bought 202,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were acquired at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. Following the purchase, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

A number of institutional investors have made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Valeant Pharmaceuticals International by 8.0% in the fourth quarter. Vanguard Group Inc. now owns 4,440,755 shares of the specialty pharmaceutical company’s stock worth $451,403,000 after buying an additional 330,079 shares in the last quarter. I.G. Investment Management LTD. raised its position in shares of Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock valued at $135,033,000 after buying an additional 314,616 shares during the period. OppenheimerFunds Inc. raised its position in shares of Valeant Pharmaceuticals International by 14.1% in the fourth quarter. OppenheimerFunds Inc. now owns 611,772 shares of the specialty pharmaceutical company’s stock valued at $62,186,000 after buying an additional 75,705 shares during the period. Diamond Hill Capital Management Inc. raised its position in shares of Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock valued at $30,635,000 after buying an additional 131,832 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock valued at $28,900,000 after buying an additional 203,760 shares during the period.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.